Exploring the next generation of antibody–drug conjugates

Tumour heterogeneity and resistance to cancer therapies

Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395

Strategies and challenges for the next generation of antibody–drug conjugates

Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Prodrugs: design and clinical applications

Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D.-M., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,681

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Junutula, J. R., Raab, H. E., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,388

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209

Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Choi, Y., Choi, Y., & Hong, S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020221 · Cited by 17

Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads

Monteiro, M. R., Nunes, N., Junior, A., Fêde, Â., Bretas, G. D. O., Souza, C. D. P., Mano, M. S., & da Silva, J. L. (2024) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s448191 · Cited by 18

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies

Balkhi, S., Bilato, G., Barbaro, A. D. L., Orecchia, P., Poggi, A. D., & Mortara, L. (2025) · Vaccines · doi:10.3390/vaccines13010069 · Cited by 18

Transferrin Receptor-Targeted Aptamer–Drug Conjugate Overcomes Blood–Brain Barrier for Potent Glioblastoma Therapy

Zhao, X., He, J., Chen, Y., Zheng, J., Li, X., Fu, T., Xie, S., Liu, X., & Tan, W. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00137 · Cited by 18

Programmable Circular Multivalent Nanobody‐Targeting Chimeras (mNbTACs) for Multireceptor‐Mediated Protein Degradation and Targeted Drug Delivery

Jiang, S., Lv, X., Ouyang, Z., Chi, H., Zeng, Y., Wang, Y., He, J., Chen, J., Chen, J., An, K., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202407986 · Cited by 19

Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors

Tolosa, E. J., Yang, L., Ayers-Ringler, J. R., Suzuki, S., Mallareddy, J. R., Schaefer-Klein, J. L., Borad, M. J., Kosari, F., Natarajan, A., & Mansfield, A. S. (2024) · Communications Biology · doi:10.1038/s42003-024-07439-0 · Cited by 16

Cancer dormancy and metabolism: From molecular insights to translational opportunities

Wang, Y., Liu, L., Zhang, X., Liang, T., & Bai, X. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218097 · Cited by 19

Spatiotemporally controlled delivery of biomacromolecules via injectable hydrogels for precision modulation of the tumor immune microenvironment

Zhou, H., Zheng, H., Yao, W., Sun, H., Yong-Guang, Y., Li, Z. S., Song, D., Zhang, Y., & Sun, T. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03970-2 · Cited by 16

The role of hydrophilic linkers in next-generation antibody-drug conjugates

Fu, Q., Kong, X., Liu, Y., Liu, M., Huang, K., Wang, P. G., & Wu, K. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114612 · Cited by 16

Charge-guided masking of a membrane-destabilizing peptide enables efficient endosomal escape for targeted intracellular delivery of proteins

Zhao, Y., Jiang, H.-L., Chen, H., Yu, J.-Z., Wang, L.-Y., Zhou, W., & Du, J.-J. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.06.022 · Cited by 13

HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy

Shao, Q., Deng, J., Wu, H., & Huang, Z.-P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1560280 · Cited by 18

Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan

Mai, N., Klar, M. M., Ferraro, E., Bromberg, M., Chen, Y., Razavi, P., Modi, S., Chandarlapaty, S., Walsh, E. M., & Drago, J. Z. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00898 · Cited by 15

Lung toxicity induced by anti-HER2 antibody – drug conjugates for breast cancer

Chai, M., Li, L., Wu, H., Liu, Y., Yi, Z., & Yu, H. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104274 · Cited by 15

Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future

Morel, V. J., Rössler, J. K., & Bernasconi, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22059 · Cited by 18

The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases

High, P. C., Guernsey-Biddle, C., Subramanian, S., Jacob, J., & Carmon, K. S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070890 · Cited by 15

Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers

Fasih, S., Welch, S. A., & Lohmann, A. E. (2024) · Current Oncology · doi:10.3390/curroncol31110522 · Cited by 15

Potential target within the tumor microenvironment - MT1-MMP

Liu, J., Li, Y., Lian, X., Zhang, C., Feng, J., Tao, H., & Wang, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1517519 · Cited by 17

Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics

Bujnak, A. C., Solaru, S. A., & Tewari, K. S. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.03.013 · Cited by 14

Immunotherapy for small cell lung cancer: current challenges and prospects

Zhong, J., Jie, G., Qin, H., Li, H., Chen, N. W., Aerxiding, P., Zou, X., & Niu, X. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00720-w · Cited by 14

Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer

Taylor, C., Patterson, K. M., Friedman, D., Bacot, S. M., Feldman, G. M., & Wang, T. (2024) · Cancers · doi:10.3390/cancers16173071 · Cited by 17

Targeting Tetraspanins at Cell Interfaces: Functional Modulation and Exosome‐Based Drug Delivery for Precise Disease Treatment

Xu, K., Feng, H., Zhao, R., & Huang, Y. (2024) · ChemMedChem · doi:10.1002/cmdc.202400664 · Cited by 17

Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy

Sun, Q., & Hong, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031238 · Cited by 15

Aptamer-engineered multivalent camptothecin conjugates synergistically orchestrate immunosuppressive microenvironment and DNA damage cascades in colorectal carcinoma

Zuo, Y., Yang, J., Wang, C., Wang, M., Chen, Y., Liu, J., Fang, Y., Chen, H., Sun, C., Zhou, X. H., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.170036 · Cited by 13

Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies

Hao, Y., & Song, Z. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.148 · Cited by 13

Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges

Conilh, L., Metrangolo, V., Crescioli, S., Reichert, J. M., & Dumontet, C. (2026) · Cell · doi:10.1016/j.cell.2026.04.016 · Cited by 14

Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development

Kwon, W., Lee, S. Y., Jeong, T., Kim, H. C., & Lee, M.-K. (2024) · Cancers · doi:10.3390/cancers16132420 · Cited by 13

Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma

Yue, T., Sun, Y., Dai, Y., & Jin, F. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101256 · Cited by 15

Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumab

Rudd, S. E., Zuylekom, J. V., Cullinane, C. M., Blyth, B. J., & Donnelly, P. S. (2025) · Chemical Science · doi:10.1039/d4sc06969b · Cited by 14

Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates

Yin, Q., Zhang, Y., Xie, X., Hou, M., Chen, X., & Ding, J. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02429-5 · Cited by 14

The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study

Peng, X., Lan, B., Wang, J., Li, Q., Wang, J., Fan, Y., Luo, Y., Chen, S., Mo, H., Li, L., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104470 · Cited by 12

Design of cathepsin-sensitive linkers for tumor-selective bioconjugate drug delivery

Giri, A., Shin, Y., Ha, J. J., Chae, S., Shrestha, P., Pham, K., Kwon, T. K., Park, J. H., Jeong, J., Lee, N. K., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114197 · Cited by 12

Antibody-drug conjugates in precision oncology

Pistilli, B., Colombo, R., Mosele, M. F., & Chandarlapaty, S. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.05.004 · Cited by 12

Novel anticancer drug discovery efforts targeting glycosylation: the emergence of fluorinated monosaccharides analogs

Costa, A. C. D. S., Teixeira, A., Reis, C. A., & Gomes, C. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2444375 · Cited by 12

Simultaneous Analysis of the Drug-to-Antibody Ratio, Free-Drug-Related Impurities, and Purity of Antibody–Drug Conjugates Based on Size Exclusion Chromatography

Song, W., Yin, L., Ren, J., Jiang, L., Huang, Z., Fan, Y., Tao, R., Duan, T., Su, Z., Cao, Y., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06661 · Cited by 12

A powerful bioorthogonal toolbox boosting the development of immune theranostics

Liu, S., Hua, C., Li, X., Yuan, P., & Xing, B. (2025) · Chemical Science · doi:10.1039/d5sc07631e · Cited by 12

DNA–drug conjugates enable logic-gated drug delivery amplified by hybridization chain reactions

Chen, S., López‐Tena, M., Russo, F., Watson, E. E., Dockerill, M., Cabello-García, J., Barluenga, S., & Winssinger, N. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03044-0 · Cited by 13

Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer

Wang, Y., Chen, Z., Wang, W., Jiang, L., Liang, X., Liu, Z., & Ma, Z. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.04.010 · Cited by 11

A single-chain fab derived drug conjugate for HER2 specific delivery

Xu, R., Zheng, Y., & Tai, W. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122798 · Cited by 11

Benzyl Ammonium Carbamates Undergo Two‐Step Linker Cleavage and Improve the Properties of Antibody Conjugates

Li, X., Patel, N. L., Kalen, J. D., & Schnermann, M. J. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202417651 · Cited by 11

Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing

O’Meara, T. A., Tarantino, P., Morganti, S., Schlam, I. M., Garrido-Castro, A. C., & Tolaney, S. M. (2025) · Current Oncology Reports · doi:10.1007/s11912-024-01628-0 · Cited by 11

Six events that shaped antibody approvals in oncology

Paul, S., & Zhou, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1533796 · Cited by 11

A comprehensive antigen-antibody complex database unlocking insights into interaction interface

Zhou, Y., Liu, W., Huang, Z., Gou, Y., Liu, S., Jiang, L., Yang, Y., & Huang, J. H. (2025) · eLife · doi:10.7554/elife.104934 · Cited by 12

Orthogonal Site-Specific Dual Bioconjugation of Aryl and Alkyl Thiols

de Geus, M. A. R., Stieger, C. E., Arafiles, J. V. V., Lotthé, J.-R. P. J., Schmieder, P., Kemnitz‐Hassanin, K., Kindt, B., Leonhardt, H., Schmitt, S., Gerlach, M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c02981 · Cited by 12

Antibody-drug conjugates (ADCs): “Smart Missiles” targeting cancer therapy

Yao, X., Lu, Y., Shi, S., & Wang, Y. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115161 · Cited by 10

Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules

Katoh, M., Loriot, Y., Nakayama, I., Hamada, A., Shitara, K., & Katoh, M. (2025) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2025.1661016 · Cited by 10

Gastrointestinal cancer: molecular pathogenesis and targeted therapy

Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 13

Tuneable redox-responsive albumin-hitchhiking drug delivery to tumours for cancer treatment

Fu, S., Zheng, A., Wang, L., Chen, J., Zhao, B., Zhang, X., McKenzie, V. A. A., Yang, Z., Leblanc, R. M., Prabhakar, R. S., et al. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00751d · Cited by 10

Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis

Wang, K., Xu, T., Wu, J., Yuan, Y., Guan, X., & Zhu, C. (2024) · The Oncologist · doi:10.1093/oncolo/oyae304 · Cited by 10

Branched Linkers for Homogeneous Antibody-Drug Conjugates: How Long Is Long Enough?

Gulyak, E. L., Komarova, O. A., Prokopenko, Y. A., Faizullina, E. A., Malabuiok, D. M., Ibragimova, A., Mokrushina, Y. A., Serova, O. V., Popova, G. P., Zhitlov, M. Y., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413356 · Cited by 10

Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy

Jiang, X., Nabil, W. N. N., Ze, Y., Dai, R., Xi, Z., & Xu, H. (2024) · Phytotherapy Research · doi:10.1002/ptr.8407 · Cited by 10

Antibody numbering schemes: advances, comparisons and tools for antibody engineering

Zhu, Z., Ashrafian, H., Mohammadian-Tabrizi, N., Matas, E. R., Girard, L., Ma, H., & Nice, E. C. (2025) · Protein Engineering Design and Selection · doi:10.1093/protein/gzaf005 · Cited by 15

Technologies for Monoclonal Antibody Discovery and Development

Han, K. H., Li, Y., Parveen, R., Venkataraman, S., & Lin, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110470 · Cited by 15

Advancements in increasing efficiency of hydrogen sulfide in therapeutics: Strategies for targeted delivery as prodrugs

Pandey, T., & Pandey, V. P. (2024) · Nitric Oxide · doi:10.1016/j.niox.2024.09.001 · Cited by 9

Cancer-targeting drug conjugates drives a new era in precise cancer treatment

Deng, J., Shi, J., Li, D., Jiao, X., Liu, J., Tian, H., Liu, N., Luo, C., Kamei, K., & Tian, C. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.110960 · Cited by 9

Novel Native Reversed-Phase Liquid Chromatography (nRPLC)/MS for Antibody–Drug Conjugates (ADCs) Characterization and Drug–Antibody Ratio (DAR) Assessment

Ma, F., Sanchez, A. C., Song, J., Kofman, E., Tomazela, D. M., Fayadat‐Dilman, L., Hettiarachchi, K., & Al‐Sayah, M. A. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c05885 · Cited by 9

Macromolecular Diamidobenzimidazole Conjugates Can Activate Stimulator of Interferon Genes

Arora, K., Sheehy, T. L., Schulman, J. A., Loken, J. R., Lehmann, Z., Kimmel, B. R., McAtee, C., Bharti, V., Stone, P. T., Weaver, A. M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c13195 · Cited by 9

Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads

Chakravorty, S., Zybina, Y., Ahn, E., Pradhan, K., Yu, N., Taylor, M., Charati, M. B., Wilson, D. C., Jeon, A. B., Blumenschein, W. M., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0682 · Cited by 9

Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond

Cheung, A., Liu, Y., Chenoweth, A. M., Montaseri, H., Esapa, B., Chudasama, V., Baker, J. R., Thurston, D. E., & Karagiannis, S. N. (2026) · Physiological Reviews · doi:10.1152/physrev.00039.2025 · Cited by 12

Engineering nanomedicine for STING pathway activation: Advancing cancer immunotherapy

Li, Z., Zhang, H., Gong, Q., & Luo, K. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114957 · Cited by 9

Understanding the Preclinical Efficacy of Antibody–Drug Conjugates

Díaz‐Tejeiro, C., Lorenzo, A. L. D. S., Poyatos‐Racionero, E., Martinez, P. B., Bartolomé, J., Calvo, E., Moreno, V., Morís, F., Pérez‐Segura, P., Győrffy, B., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312875 · Cited by 8

Diverse Roles of Antibodies in Antibody–Drug Conjugates

Yamaguchi, A., & Manning, H. C. (2025) · Pharmaceuticals · doi:10.3390/ph18020180 · Cited by 8

How to design next-generation of antibody-drug conjugates for cancer treatment: Lessons from unsuccessful clinical trials

Jian, A., Zhao, G., Zhou, J., Wang, S., & Li, N. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217535 · Cited by 8

Surface molecularly imprinted polymer nanocatalytic probes for scattering spectral analysis

Li, J., Wang, Z., Wen, G., Liang, A., & Jiang, Z. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118283 · Cited by 8

Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity

Long, Y., Tang, B., Xie, F., Liu, L., Zhou, Y., Dong, J., Wang, J., Sun, C., Wang, Y., Li, R., et al. (2025) · Advanced Science · doi:10.1002/advs.202502270 · Cited by 9

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Silverstein, J. F., Smick, A., Johnson, B., & Konecny, G. E. (2025) · Future Oncology · doi:10.1080/14796694.2025.2513848 · Cited by 8

Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates

Ochtrop, P., Jagtap, A. P., Felber, J. G., Vogt, S., Herterich, S., Mai, I., Cyprys, P., Schmitt, S., Payer, S., Kitowski, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68605-y · Cited by 8

From prediction to precision: how immunopeptidomics advances neoantigen discovery

Shapiro, I. E., & Bassani-Sternberg, M. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.02.003 · Cited by 9

Personalized Nanomedicine: Integrating Molecular Stratification with Engineered Delivery Systems

Sharon, S., Mainkar, G., & Zangi, L. (2026) · Journal of Nanotheranostics · doi:10.3390/jnt7020009 · Cited by 8

Antibody-drug conjugates as a novel therapeutic modality to treat recurrent refractory germ cell tumors

Udvorková, N., Fekiačová, A., Majtánová, K., Mego, M., & Kučerová, L. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00200.2024 · Cited by 8

Update of antibody–drug conjugates for hematological malignancies

Sun, W., Hu, S., & Wang, X. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001065 · Cited by 8

Generation of binder-format-payload conjugate-matrices by antibody chain-exchange

Vasic, V., Dickopf, S., Spranger, N., Rosenberger, R.-S., Fischer, M., Mayer, K., Larraillet, V., Bates, J. A., Maier, V., Sela, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53730-3 · Cited by 8

Advanced breast cancer immunotherapy: Surface modification of NK cells for embedding antibody-drug conjugates

Lim, S. Y., Han, S., Kim, Y. H., Kim, H. B., Kim, Y., Park, J., Yun, J., Yong, S., Won, Y., & Lim, K. S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118245 · Cited by 8

Research progress of immune checkpoint inhibitors in ovarian cancer

Zhao, L., Zhai, Y., & Niu, G. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00177 · Cited by 7

Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2− Breast Cancers

Gough, M., Kwah, K. K. X., Khan, T., Ghosh, S., Sun, B., Lee, C. Y. J., Sokolowski, K. A., Tse, B. W.-C., Wickramasuriya, L., Ferguson, K., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2865 · Cited by 6

Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC

Probst, P., Attinger-Toller, I., Bertrand, R., Stark, R., Santimaria, R., Schlereth, B., Grabulovski, D., & Spycher, P. R. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0983 · Cited by 7

Integrated strategy for biotransformation of antibody–drug conjugates and multidimensional interpretation via high-resolution mass spectrometry

Li, Z., Zhang, J., Wu, Y., Wang, F., & Cai, T. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100081 · Cited by 8

TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile

Vogl, A. M., Schmitt, S., Mai, I., Machui, P., Herterich, S., Leonardi, N., Cyprys, P., Hauswald, D., Ochtrop, P., Kozlowska, I., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0254 · Cited by 7

Novel Aptamer-Drug Conjugate for Targeted Therapy in Triple-Negative Breast Cancer

Xu, F., Xu, J., Han, F., Wang, K., Wang, F., Yu, H., & Guan, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00492 · Cited by 7

Integrative genomic identification of therapeutic targets for pancreatic cancer

Guo, J. A., Gong, D. H., Evans, K. E., Takahashi, K., Jambhale, A. D., Shiau, C., Yu, P. Z., Wang, S., Wu, W., Chugh, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116191 · Cited by 9

Constructing the cure: engineering the next wave of antibody and cellular immune therapies

Bailey, S. R., Bartee, E., Daniels, K. G., Heery, C. R., Kaumaya, P. T. P., Lesinski, G. B., Lowinger, T. B., Nelson, M. H., Rubinstein, M. P., Wittling, M. C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011761 · Cited by 8

Theranostic antibody conjugates: A review of recent trends and applications in cancer

Kheyrolahzadeh, K., Mojahedi, M., Tohidkia, M. R., & Aghanejad, A. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108915 · Cited by 7

Payload-dependent photostability of antibody-drug conjugates

Thiess, C. O., Mäder, K., Mahler, H., & Wöll, S. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114867 · Cited by 7

SPARC: A Multipayload ADC Architecture for Programmable Drug Combinations

Sun, W., Weng, W., Shi, J., Ma, B., DeMarco, K. D., Gui, F., Jin, R. F., Ruscetti, M. A., Li, J., Hu, W., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00239 · Cited by 9

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models

High, P. C., Liang, Z., Guernsey-Biddle, C., Subramanian, S., Shyu, Y.-M., Aldana, A. M., Toh, Y., & Carmon, K. S. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102363 · Cited by 10

Engineered nano-bacteria hybrids for precision cancer immunotherapy

Yu, L., Qiu, Y., Li, R., Xu, Z. C., & Li, R. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102484 · Cited by 7

The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities

ElBeblawy, R., Jani, C., Pérez‐Granado, J., Gramling, M., & Desai, A. P. (2025) · Cancer Medicine · doi:10.1002/cam4.71432 · Cited by 9

Dynamic thiol-disulfide exchange regulated protein assembly for adaptive and functional material design

Gao, A., Guo, X., Wen, J., Yang, P., & Ren, H. (2026) · Chemical Communications · doi:10.1039/d5cc06437f · Cited by 7

Carrier-free drugs as smart nanomaterials for cancer theranostics

Parthasarathy, N., Shin, J., Thangam, R., Rajan, P. C., Rithisa, B., Shyamsivappan, S., Fabiola, M., Kang, H., & Vivek, R. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.217601 · Cited by 7

Receptor-ubiquitination-targeting antibody-drug conjugates for enhanced endocytosis and lysosomal delivery

Zhuang, X., Lin, L., Li, J., Yu, G., Chen, B., Xu, Y., Chen, S., Yi, W., & Pan, L. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.02.015 · Cited by 6

Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions

Cheng, B., Gong, L., Wang, Z. P., Peng, P., Xu, K., Huang, H., & Wu, P. (2026) · MedComm · doi:10.1002/mco2.70699 · Cited by 9

Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer

Capuozzo, M., Santorsola, M., Ianniello, M., Ferrara, F., Zovi, A., Petrillo, N., Castiello, R., Fantuz, M., Ottaiano, A., & Savarese, G. (2024) · Diseases · doi:10.3390/diseases12050087 · Cited by 8

Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer

Moore, E. J., Rice, M., Roy, G., Zhang, W., & Marelli, M. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2339993 · Cited by 9

Precision epitope editing: A path to advanced immunotherapies

Ji, R.-J., Wang, M.-Y., & Zhang, Y. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100226 · Cited by 8

Modular Synthesis of Anti-HER2 Dual-Drug Antibody-Drug Conjugates Demonstrating Improved Toxicity

Nervig, C. S., Rice, M., Marelli, M., Christie, R. J., & Owen, S. C. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00398 · Cited by 7

A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors

Hu, Y., Du, X., Yuan, J., Gong, X., Zhu, Y., Lin, X., Lin, X., Zheng, F., Ran, Y., Na, Z., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217685 · Cited by 7

Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development

Ma, Q., Puro, D., Wang, F. X. C., Yao, H.-P., & Wang, M. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104057 · Cited by 7

Efficacy and safety of antibody–drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials

Ren, J., Chen, Z.-Y., Bai, Y., & Han, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1377924 · Cited by 6

Production of site-specific antibody conjugates using metabolic glycoengineering and novel Fc glycovariants

Bernstein, Z. J., Gierke, T. R., Dammen‐Brower, K., Tzeng, S. Y., Zhu, S. E., Chen, S. S., Wilson, D. S., Green, J. J., Yarema, K. J., & Spangler, J. B. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108005 · Cited by 6

Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy

Mihaylova, R., Momekova, D. B., Elincheva, V., & Momekov, G. (2024) · Pharmaceuticals · doi:10.3390/ph17121701 · Cited by 6

Pincer‐Type Pt(II)‐NHC Antibody‐Drug Conjugate for HER‐2‐Targeted Chemoimmunotherapy

Huang, T., Huang, W., Huang, G., Wei, X., Huang, Y., Liu, T., Liu, Y., Ni, W., & Che, C. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403449 · Cited by 6

Next Generation Antibody–Drug Conjugates: Molecular Design Innovations And Overcoming Resistance – A Comprehensive Review

Hari Nandhini.A, D. S. S. M. B. R. (2025) · Vascular and Endovascular Review · doi:10.64149/j.ver.8.16s.217-224

Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Metrangolo, V., & Engelholm, L. H. (2024) · Cancers · doi:10.3390/cancers16020447 · Cited by 77

Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs

Wu, D., Yang, K., He, R., Yin, R., & Shui, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1669592 · Cited by 25

Antibody-drug conjugates: mechanism, progress and future directions of cancer targeted therapy

Li, M., Wu, G., Chen, B., Zheng, Z., Ning, X., Li, J., De, Z., Li, J., & Song, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02817-0

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209